Our Progress

Toward Development of A Cure

Rare Disease Facts

Over 7,000 different rare diseases are know today, with more being discovered each day; 30 million people in the United States are living with a rare disease. This equates to 1 in 10 Americans or 10% of the U.S. Population.

Majority (80%) of rare diseases are genetic in origin, and thus are present throughout a person’s life, even if symptoms do not immediately appear. Approximately 50% of rare diseases do not have a disease specific foundation supporting or researching their rare disease. 

95% of all rare diseases do not have a single FDA approved treatment

AGU and Drug Development Process

Every new treatment follows FDA approval process, where a drug is determined to provide benefits that outweigh its known and potential risks for the intended population. To determine the benefits and risks of a drug/treatment, a researcher investigates effects of the drug, drug delivery and doses in animals before submitting an application to try the treatment in humans.  It is  Investigational New Drug (IND) application and FDA approval allows to give the new drug in patients. 

We've been funding two different treatments for Aspartylglucosaminuria since 2013: Chaperone Therapy and Gene Replacement Therapy. Both drug developments go through the same development process. Chaperone therapy uses already existing medicines to treat a new disease (AGU), hence after testing it in a patient's cultured cells, governing authority allowed it to progress into a clinical trial. Gene replacement therapy went through several years of a rigorous pre-clinical animal testing to prove efficacy and safety of the chosen formulation of the gene therapy medicine. The results of this study was published in 2021. 

Since then we 

We are currently  (our progress is indicated with the orange arrow on the chart above):  

Published Research Funded by Rare Trait